



Supplementary Figure 1: Examples of tissue microarray immunofluorescence staining for VEGFR-2 and c-MET.




Key: VEGFR-2, red staining; c-MET, green staining; VEGFR-2/c-MET co-localisation, orange staining and white arrows; white is stroma stained by collagen IV and blue nuclei by DAPI. Supplementary Figure 1B and 1D- white line, 200 μ M; Supplementary Figure 1B and 1D- white box (insert) refers to magnified image shown in Figure 1C and 1E, respectively; Supplementary Figure 1C & 1E- white line, 100 μ M.


Supplementary Figure 2: Progression-free survival for SNPs VEGF-A rs3025033 (A-B) and VEGFR-2 rs1870377 (C-D) in the chemotherapy group (A/C) and chemotherapy plus bevacizumab group (B/D).




VEGF-A rs3025033 - chemotherapy (control group)



VEGF-A rs3025033 - chemotherapy + bevacizumab (experimental group)




VEGFR-2 rs1870377 - chemotherapy (control group)



VEGFR-2 rs1870377 - chemotherapy + bevacizumab (experimental group)

Supplementary Figure 3: Summary of findings for c-MET/VEGFR-2 co-localisation and SNP VEGFR-2 rs2305945.





	T/T	G/T	G/G
c-MET/VEGFR-2 ^{LOW}	33	25	6
c-MET/VEGFR-2 ^{HIGH}	26	39	13

P=0.047

High c-MET/VEGFR-2 co-localisation

Reduced PFS in bevacizumab treated group

Reduced OS in bevacizumab treated group



VEGFR-2 rs2305945 - chemotherapy + bevacizumab (experimental group)

c-MET/VEGFR-2 co-localisation - chemotherapy + bevacizumab (experimental group)